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Abstract
The development of efficient anti-cancer therapy has been a topic of intense interest for several decades. Combined
administration of certain molecules and immune cells has been shown to be an effective form of anti-cancer therapy.
Here, we examined the effects of administering an immune stimulating peptide (WKYMVm), 5-fluoro-uracil (5-FU), and
mature dendritic cells (mDCs) against heterotopic cancer animal model. Administration of the triple combination
strongly reduced tumor volume in CT-26-inoculated heterotopic cancer animal model. The induced anti-tumor activity
was well correlated with FAS expression, caspase-3 activation, and cancer cell apoptosis. The triple combination
treatment caused recruitment of CD8 T lymphocytes and natural killer (NK) cells into the tumor. The production of two
cytokines, IFN-c and IL-12, were strongly stimulated by administration of the triple combination. Depletion of CD8 T
lymphocytes or NK cells by administration of anti-CD8 or anti-asialoGM1 antibody inhibited the anti-tumor activity and
cytokine production of the triple combination. The triple combination strongly inhibited metastasis of colon cancer cells
in a heterotopic cancer animal model as well as in a metastatic cancer animal model, and enhanced the survival rate of
the mice model. Adoptive transfer of CD8 T lymphocytes and NK cells further increased the survival rate. Taken together,
we suggest that the use of triple combination therapy of WKYMVm, 5-FU, and mDCs may have implications in solid
tumor and metastasis treatment.
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Introduction
Development of anti-cancer therapy has been an important
issue for several decades [1], [2]. Treatment with anti-cancer
agents is one of the most widely utilized modes of anti-tumor
therapy. Various anti-cancer agents have been developed,
including 5-fluoro-uracil (5-FU) [3]. Mechanistically, anti-cancer
agents have been reported to cause apoptosis of cancer cells, which
induces the initiation of anti-cancer immune responses [4]. In the
host immune system, dendritic cells (DCs) appear to play a key role
in anti-tumor activity. DCs recognize and uptake tumor antigens,
and present the processed antigens on major histocompatibility
complex molecules [5], [6], [7]. Thus, DCs can stimulate T
lymphocytes, resulting in cytotoxic T lymphocyte activity. DCs
also secrete several cytokines which are important in efficient anti-
tumor activity [7].
WKYMVm was identified as an immune-stimulating synthetic
peptide from a peptide library screening [8], [9]. WKYMVm
stimulates leukocytic cells such as monocytes, neutrophils, natural
killer (NK) cells, and DCs [9], [10], [11], [12]. Because of
monocyte and neutrophil stimulation, chemotactic migration,
superoxide anion production, and the production of certain
inflammatory mediators such as leukotriene B4 is induced by
WKYMVm [9], [13], [14]. NK cell stimulation with WKYMVm
results in cytolytic activity and chemotactic migration [11]. The
peptide stimulated chemotactic migration of DCs [12]. Three
members of the formyl peptide receptor (FPR) family have been
reported to be cognitive cell surface receptors for WKYMVm in
humans [15], [16]. Mouse FPR has also been reported to act as a
WKYMVm receptor [17]. Although WKYMVm has been
reported to stimulate leukocytes which play important roles
against cancer antigens, little is known about the role of
WKYMVm in anti-cancer activity.
Combined administration of certain molecules can induce
effective anti-cancer activity. Although various anti-cancer agents
or anti-cancer therapies have been reported, development of new
anti-cancer therapies which are effective and specific with low
toxicity is still necessary. In this study we investigated the
therapeutic activity of WKYMVm when it was administrated
with an anti-cancer agent (5-FU) and a natural vaccine adjuvant
(mature DCs, mDCs). The mechanism of action of the triple
combination therapy was also characterized.
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Combined administration of WKYMVm, 5-FU, and mDCs
causes anti-tumor activity in heterotopic cancer animal
model
The putative anti-tumor activity of WKYMVm, 5-FU, or
mDCs was examined. WKYMVm, 5-FU, or mDCs were first
administered singly. For example, as shown in Fig. 1A,
WKYMVm (100 mg/head) was injected four times at 12 h
intervals. Single administration caused a slight decrease in
t u m o rv o l u m e( F i g .1 B ) .W h e nt h ea g e n t sw e r et e s t e di np a i r s
(WKYMVm+5-FU; WKYMVm+mDCs; mDCs+5-FU) against
an animal model, anti-tumor activity was enhanced (Fig. 1B).
The presence of 5-FU appeared to further potentiate anti-
tumor activity (Fig. 1B, 5-FU+WKYMVm and 5-FU+mDCs).
Moreover, when the triple combination (WKYMVm+5-
FU+mDCs) was administered to the heterotopic cancer animal
m o d e l ,t h em o s tp o t e n ta n t i - tumor activity was observed
(Fig. 1B).
Combined administration of WKYMVm, 5-FU, and mDCs
elicits tumor apoptosis
Since tumor apoptosis is closely related to anti-tumor activity,
the effect of each administration on tumor apoptosis was
measured. As shown in Fig. 2, single administration of
WKYMVm, 5-FU, or mDCs induced low levels of tumor cell
death, and double combinations showed further increase in cell
death, with the triple combination resulting in dramatically
increased tumor cell death in the heterotopic cancer animal
model (Fig. 2). The TUNEL-positive cells coincided with FAS
expression, indicating that the tumor cell death observed is due to
apoptosis (Fig. 2). Caspase-3 activity upon treatment was
determined by immunofluorescence staining using anti-phospho-
caspase-3 antibody. Consistent with the TUNEL staining and FAS
expression results, caspase-3 activation increased as the number of
combined agents increased, with the WKYMVm+5-FU+mDCs
triple combination inducing a dramatic increase in caspase-3
activity (Fig. 2). The levels of tumor cell apoptosis and caspase-3
activity correlate well with the tumor volume data in Fig. 1B.
Figure 1. Anti-tumor activity of WKYMVm, 5-FU, and mature DCs in a heterotopic cancer animal model. (A) Protocol for the study of
anti-tumor activity of WKYMVm, 5-FU, and mDCs. (B) The triple combination of WKYMVm, 5-FU, and mDCs has the most potent anti-tumor activity.
CT-26 cells (5610
5 cells in 100 ml of PBS) were injected s.c. into the right flank of Balb/c mice (n=8) on day 23. The mice were treated according to
the protocol in (A). Tumor volume was measured and the data are shown as the mean 6 SEM (n=8).
***, P,0.001 compared with the control.
doi:10.1371/journal.pone.0030522.g001
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recruitment of CD8 T cells and NK cells into the tumor
To initiate an anti-tumor immune response, leukocytic cells
need to be recruited into the tumor area [18]. Since administration
of the triple combination (WKYMVm+5-FU+mDCs) elicited
potent anti-tumor activity against the heterotopic cancer animal
model, we examined what types of cells are recruited into the
tumor by immunohistochemistry using anti-CD3, anti-CD4, anti-
CD8, anti-CD11b, or anti-DX5 antibody. Administration of the
triple combination caused dramatic recruitment of CD8 T
lymphocytes and NK cells into the tumor area, as well as slight
recruitment of CD4 T lymphocytes (Fig. 3A).
Administration of anti-CD8 monoclonal antibody prior to the
triple combination caused dramatic inhibition of CD8 T
lymphocyte recruitment into the tumor area, without affecting
NK cell recruitment (Fig. 3B). When anti-asialoGM1 antibody was
administered prior to injection of the triple combination, NK cell
recruitment into the tumor area was strongly blocked, but CD8 T
lymphocyte recruitment was not affected (Fig. 3D). Anti-CD4
antibody administration prior to injection of the triple combina-
tion did not affect CD8 T lymphocyte or NK cell recruitment
(Fig. 3C).
CD8 T cells and NK cells play major roles in the anti-
tumor activity of the triple combination therapy
For efficient activation of anti-cancer activity in an experimental
animal, several leukocyte types communicate with each other and
act concertedly. We examined the relative contribution of
individual leukocyte types on the anti-tumor activity induced by
the triple combination therapy, by administrating antibodies
against each leukocyte. When anti-CD8 antibody was adminis-
tered to the heterotopic cancer animal model, the anti-tumor
activity of the triple combination was almost completely inhibited
(Fig. 4A). Administration of anti-asialoGM1 antibody elicited
partial inhibition of the anti-tumor activity of the triple
combination therapy (Fig. 4B). However, administration of the
anti-CD4 antibody did not affect the anti-tumor activity of the
triple combination (data not shown). These results indicate that
CD8 T cells and NK cells play major roles in the anti-tumor
activity of the triple combination of WKYMVm, 5-FU, and
mDCs.
Administration of the WKYMVm, 5-FU, and mDCs triple
combination elicits a change of cytokine profile in a
heterotopic cancer animal model
We tested whether administration of WKYMVm, 5-FU, and
mDCs in various combinations causes changes in cytokine profile
compared to the control tumor lysate. As shown in Fig. 5A,
administration of the triple combination caused dramatic changes
in the levels of IFN-c and IL-12 produced from tumor lysates in
the heterotopic cancer animal model. The production of IFN-c in
the tumor gradually increased as the number of combined agents
increased, with double combinations generally showing more IFN-
c production than single administration, and the triple combina-
tion showing the highest level of IFN-c production (Fig. 5A). When
IL-12 levels were measured, we found that single administration of
each agent did not induce production of IL-12, and among the
double combinations, only the combination of WKYMVm+mDCs
enhanced IL-12 production in the animal model (Fig. 5B).
Administration of the triple combination (WKYMVm+mDCs+5-
FU) dramatically increased IL-12 production to a level that was
two-fold higher than the WKYMVm+mDCs double combination
(Fig. 5B).
Administration of the triple combination was also observed to
enhance the production of IFN-c and IL-12 in the peripheral
blood (Fig. 5C–5F). To examine the role of CD8 T lymphocytes
Figure 2. Administration of WKYMVm, 5-FU, and mDCs causes tumor cell apoptosis in a heterotopic cancer animal model. Balb/c
mice were inoculated with CT-26 cells and treated with WKYMVm, 5-FU, and mDCs according to the protocol in Fig. 1A. Mice were euthanized 42
days after tumor inoculation and tumors were surgically excised, and processed for hematoxylin and eosin staining, immunohistochemistry for FAS
staining, caspase-3 staining, and TUNEL staining, as described in Materials and Methods. The data presented is representative of three independent
experiments.
doi:10.1371/journal.pone.0030522.g002
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combination administration, anti-CD8 or anti-asialoGM1 anti-
body was administered prior to triple combination treatment.
Administration of anti-CD8 or anti-asialoGM1 antibody blocked
triple combination-induced IFN-c and IL-12 production in the
peripheral blood (Fig. 5C–5F). These results indicate that CD8 T
lymphocytes and NK cells play a role in IFN-c and IL-12
production induced by triple combination treatment.
Anti-metastasis activity of combined administration of
WKYMVm, 5-FU, and mDCs
When developing an effective anti-tumor therapeutic agent, it is
important to develop agents which inhibit tumor recurrence [19].
The metastatic ability of cancer cells to migrate from their origin
to other target tissues is one of the major reasons that make it
difficult to develop an efficient anti-cancer agent [20], [21]. In our
heterotopic cancer animal model, we observed that subcutaneous
inoculation of CT-26 colon cancer cells caused spontaneous
metastasis of the cells into the lung tissue (Fig. 6A). Administration
of the triple WKYMVm+mDCs+5-FU combination almost
completely blocked metastasis of colon cancer cells to the lungs
(Fig. 6A). This triple combination-induced anti-metastasis activity
was blocked by the administration of anti-CD8 or anti-asialoGM1
antibody (Fig. 6A), indicating that the anti-metastasis activity is
mediated by CD8 T lymphocyte and NK cell activity.
We also used an artificial metastasis animal model to test the
effect of different combinations of WKYMVm, 5-FU, and mDCs
against metastasis. Injection of CT-26 colon cancer cells into the
tail vein causes metastasis into the lungs. Lungs were isolated 14
days after CT-26 cell injection. Dramatic lung metastasis was
observed with vehicle treated mice (Fig. 6B). Single or double
combinations of WKYMVm, mDCs, and 5-FU inhibited tumor
metastasis to varying degrees to reduce lung metastasis, and the
most potent effect was observed with the triple combination
(Fig. 6B).
Combined administration of WKYMVm, 5-FU, and mDCs
enhances survival rates in a heterotopic cancer animal
model
The survival rate of the heterotopic cancer animal model upon
combined treatment was examined. We tested the combinations
that showed relatively high anti-tumor activity in our previous
assays above; 5-FU alone, 5-FU+WKYMVm, 5-FU+mDCs, and
5-FU+mDCs+WKYMVm. Administration of 5-FU alone, 5-
FU+mDCs, or 5-FU+WKYMVm only slightly increased survival
rate, but administration of the triple 5-FU+mDCs+WKYMVm
combination strongly enhanced survival rate (Fig. 7A). All mice in
the control group were died after 65 days, whereas 80% of the
triple combination-administered group was alive at 80 days
(Fig. 7A).
To test if adoptive transfer of CD8 T lymphocytes and NK cells
could enhance the triple combination-induced survival of the
heterotopic cancer animal model mice, we inoculated an increased
number of colon cancer cells (1610
6 cells/head) into mice. In this
Figure 3. Triple administration of WKYMVm, 5-FU, and mDCs causes the recruitment of CD8 T lymphocytes, CD4 T lymphocytes,
and NK cells in a heterotopic cancer animal model. (A) Balb/c mice were inoculated with CT-26 cells and treated with WKYMVm, 5-FU, and
mDCs according to the protocol in Fig. 1A. CD8 T cells, CD4 T cells or NK cells were depleted by i.p. injection of 100 mg of anti-CD8 (B), anti-CD4 (C) or
anti-asialoGM1 antibody (D) into Balb/c mice. Mice were euthanized 42 days after tumor inoculation and tumors were surgically excised, and
processed for immunostaining using anti-CD3, anti-CD4, anti-CD8, and anti-asialoGM1 antibodies, as described in Materials and Methods. CD3
+ CD8
+
cells, CD3
+ CD4
+cells, and CD11b
+ DX5
+ cells indicate CD8 T lymphocytes, CD4 T lymphocytes, and NK cells, respectively. The data presented is
representative of three independent experiments.
doi:10.1371/journal.pone.0030522.g003
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survival rate to 40% at 80 days (Fig. 7B). Under these conditions
adoptive transfer of CD8 T lymphocytes or NK cells was
performed. Adoptive transfer of CD8 T lymphocytes or NK cells
only slightly increased the survival rated caused by triple
combination administration, whereas combined adoptive transfer
of CD8 T lymphocytes and NK cells dramatically increased
survival rate (Fig. 7B). These results indicate that both CD8 T
lymphocytes and NK cells can enhance the survival rate induced
by the triple combination in the heterotopic cancer animal model.
Discussion
In this study, we demonstrated that administration of the triple
combination of the synthetic peptide WKYMVm, mDCs, and 5-
FU endows potent anti-cancer immunity. Single (WKYMVm,
mDCs, or 5-FU) or double (WKYMVm+mDCs, 5-FU+W-
KYMVm or 5-FU+mDCs) treatment of mice slightly decreased
tumor volume, but administration of the triple combination
dramatically inhibited tumor growth (Fig. 1). The tumor volume
measurement results were correlated well with FAS expression,
caspase-3 activity, and TUNEL staining results (Figs. 1 and 2).
According to previous reports, IFN-c is known to induce the
expression of cell death receptors such as FAS [22], [23]. In this
study, we showed that the administration of different combinations
of WKYMVm, 5-FU, or mDCs can induce IFN-c expression, with
the triple combination causing the most enhanced IFN-c
production (Fig. 5A). The expression level of IFN-c was well
correlated with the anti-tumor activity of each combination,
suggesting that IFN-c induced by the administration of each agent
or combination is critically involved in anti-tumor activity in the
animal model.
IL-12 can prime or stimulate CD4 T cells, CD8 T cells and NK
cells [24], [25], [26]. In this study, only certain combinations,
namely WKYMVm+mDCs and the triple combination could
induce IL-12 expression in the heterotopic cancer animal model
(Fig. 5B). Single administration of WKYMVm or mDCs did not
induce IL-12 production (Fig. 5B). This suggests that the
stimulation of mDCs with WKYMVm is responsible for efficient
induction of IL-12 in the animal model. Since WKYMVm is a
ligand for the FPR family, it appears likely that the activation of
the FPR family induces IL-12 expression from mDCs. In the
survival rate experiment, triple administration of WKYMVm+5-
FU+mDCs induced a strong enhancement of survival rate in a
heterotopic cancer animal model, but 5-FU+mDCs treatment had
a much lesser effect (Fig. 7). Since IL-12 production is strongly
induced by the triple combination but not by 5-FU+mDCs
(Fig. 5B), it may be possible that the triple combination enhances
survival rate by stimulating the production of soluble factors such
as IL-12.
NK and CD8 T cells were recently reported to be important in
cancer regression [27], [28], [29]. Here, we demonstrated that
CD8 T and NK cells were enriched in tumors when the triple
combination was administered (Fig. 3), and depletion of CD8 T
cells or NK cells increased tumor growth (Fig. 4). In addition,
depletion of CD8 T cells or NK cells reduced the levels of induced
IFN-c and IL-12 (Fig. 5C–5F). These results indicate that CD8 T
cells and NK cells are involved in the anti-tumor effect of the triple
combination. Triple administration of WKYMVm, mDCs and 5-
FU also elicited an anti-metastasis effect in a heterotopic cancer
animal model (Fig. 6). Intravenous injection of ATRA-cationic
liposome/IL-12 pDNA complexes was shown to enhance the
growth inhibition of metastatic lung tumors in mice [30],
supporting our notion that IL-12 production may be associated
with anti-metastasis activity of the triple combination.
In this study we demonstrated that CD8 T cells and NK cells play
important roles in the anti-tumor activity of the triple combination.
Previously we reported that NK cells express functional FPR family,
and stimulation of NK cells with FPR agonist WKYMVm elicits
IFN-c production [11]. In this study we also found that mouse NK
cells express FPR family, and stimulation of mouse NK cells with
WKYMVm elicits the production of IFN-c (data not shown). This
finding explains WKYMVm-induced NK cell activation is essen-
tially required for the anti-tumor activity of the triple combination
against heterotopic cancer animal model. In terms of the activation
ofCD8Tcellsandtheirroleintheheterotopiccanceranimalmodel,
previously we showed that T cells do not express receptors for
WKYMVm [31]. Since CD8 T cells can be activated by mDCs and
IL-12[32],[33], itwill bereasonableto think that the administration
of triple combination containing WKYMVm can induce the
activation of CD8 T cell will be mediated by mDCs or IL-12.
In conclusion, triple combination immunotherapy with mDCs,
the synthetic peptide WKYMVm, and 5-FU was superior to single
or double treatment in inhibiting established primary tumors and
metastasis, as well as prolonging survival. The increase in
therapeutic efficacy was due to effects that occurred locally
(enhanced levels of FAS and caspase-3 expression) and systemi-
cally (increased production of IFN-c and IL-12). Therefore, use of
Figure 4. CD8 T lymphocytes and NK cells are involved in the
anti-tumor activity induced by the combination of WKYMVm,
5-FU, and mDCs in a heterotopic cancer animal model. Balb/c
mice were inoculated with CT-26 cells and treated with WKYMVm, 5-FU,
and mDCs according to the protocol in Fig. 1A. CD8 T cells or NK cells
were depleted by i.p. injection of 100 mg of anti-CD8 (A) or anti-
asialoGM1 antibody (B) into Balb/c mice. Tumor volume was measured
and the data are shown as the mean 6 SEM (n=8).
*, P,0.05,
***,
P,0.001 compared with the control.
doi:10.1371/journal.pone.0030522.g004
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Materials and Methods
Mice
The Institutional Review Committee for Animal Care and Use
at Dong-A University specifically approved this study (approval
ID: DIACUC 07-6). Balb/c mice (males, 6–8 weeks old) were
obtained from the Jackson Laboratory.
Cell culture and material
CT-26 cells (CRL-2638; ATCC American Type Culture
Collection) are a colon adenocarcinoma cell line derived from
Balb/c mice. CT-26 cells were maintained in RPMI 1640
(Invitrogen, Carlsbad, CA) containing 10% heat-inactivated fetal
bovine serum and antibiotics at 37uC in a 5% CO2 humidified
incubator. The synthetic peptide, WKYMVm, was synthesized at
Anygen (Kwangju, Korea). The purity of synthesized WKYMVm
was .98%. 5-FU was purchased from Choongwae, Pharma Co.
(Seoul, Korea).
Figure 5. Effects of WKYMVm, 5-FU, and mDCs on IFN-c and IL-12 production in an experimental animal model. Balb/c mice were
inoculated with CT-26 cells and treated with WKYMVm, 5-FU, and mDCs according to the protocol in Fig. 1A. (A, B) IFN-c and IL-12 levels were
measured from tumor tissue lysate. (C–F) IFN-c and IL-12 levels in peripheral blood upon triple combination treatment were measured. 100 mgo f
anti-CD8 (C, D) or anti-asialoGM1 antibody (E, F) was injected i.p. to Balb/c mice. Data are shown as the mean 6 SEM (n=8).
*, P,0.05,
***, P,0.001,
compared with the control value;
#, P,0.05, significantly different from the WKYMVm+5-FU+mDCs-treated control.
doi:10.1371/journal.pone.0030522.g005
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Bone marrow cells were cultured for 5 days in DC medium
(RPMI 1640 medium with 10% FBS, 2 mM L-glutamine, 50 mM
b-mercaptoethanol, antibiotics) in the presence of mouse GM-CSF
(1000 U/ml) and IL-4 (500 U/ml), as described [34]. GM-CSF
and IL-4 were replenished on day 2 and 4. On day 5, cells were
collected and transferred onto a new plate with DC medium and
stimulated with lipopolysaccharide (100 ng/ml; Sigma), CpG
oligodeoxynucleotide 1826 (10 mg/ml), and CT-26 lysate
(100 mg/ml) for 2 days to induce maturation. On day 7, DCs
were collected for use as vaccines.
Tumor growth and survival
To measure tumor growth, CT-26 cells (5610
5 cells in 100 mlo f
PBS) were injected s.c. into the right flank of Balb/c mice (n=8)
on day 23. On days 0 and 1, 5-FU (100 mg/100 ml) was injected
s.c. into Balb/c mice. On day 2, mice were treated with four
injections of WKYMVm (100 mg/100 ml) and mDCs (1610
6 cells)
at 12 h-intervals. On days 4 and 5, 5-FU (100 mg/100 ml) was
injected s.c. into Balb/c mice. Subsequently, the mice were treated
with s.c. injection of 5-FU, mDCs and WKYMVm once weekly
for 4 weeks. Tumor volume was determined by the following
formula: tumor volumes (in mm
3)=length (mm)6width (mm)
2/2
Figure 6. Anti-metastasis activity of WKYMVm, 5-FU, and mDCs. (A) Balb/c mice were inoculated with CT-26 cells and treated with WKYMVm,
5-FU, and mDCs according to the protocol in Fig. 1A. CD8 T cells or NK cells were depleted by injecting 100 mg of anti-CD8 or anti-asialoGM1 antibody
i.p. into Balb/c mice. On day 42, mice were sacrificed and tumor nodules on the surface of the lungs were observed. (B) CT-26 cells (2610
5 cells in
100 ml of PBS) were injected into the tail vein of Balb/c mice. After 14 days, mice were sacrificed and hematoxylin and eosin staining was performed
using the isolated lungs. The images shown are representative of eight independent experiments.
**, P,0.01,
**, P,0.01 compared with the control.
doi:10.1371/journal.pone.0030522.g006
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for survival following tumor inoculation and treatment.
Hematoxylin and eosin and immunofluorescence
staining
Mice were euthanized 42 days after tumor inoculation, and
tumors were surgically excised, fixed for 24 h in 10% neutral
phosphate buffered formalin (NBF), embedded in paraffin, and
sectioned and stained with hematoxylin and eosin for morphological
analysis. For immunostaining, the following primary antibodies were
used: anti- mouse Fas (Santa Cruz), anti-mouse cleaved caspase-3
(Cell Signaling), FITC-conjugated anti-mouse CD3 (BD Pharmin-
gen), PE-conjugated anti-mouse CD4 (BD Pharmingen), PE-
conjugated anti-mouse CD8 (BD Pharmingen), FITC-conjugated
anti- mouse CD11b (BD Pharmingen), and PE-conjugated anti-
mouse DX5 (BD Pharmingen) antibody. For confocal microscopy,
fixed tumor tissues were stained with FITC-conjugated anti-mouse
IgG and Alexa 594-conjugated anti-mouse IgG (BD Pharmingen).
In situ TUNEL staining
Terminal deoxy-nucleotidyl transferase-mediated digoxigenin-
dUTP nick end labeling (TUNEL) was performed to detect
apoptotic cells in the tumor tissues. Paraffin sections were
deparaffinized, hydrated, treated with 3% H2O2 for 5 min, and
rinsed with PBS for 15 min, and the In situ Death Detection Kit,
POD, was used (Roche, Penzberg, Germany). Briefly, digoxigenin-
dUTP end-labeled DNA was detected with anti-digoxigenin-
peroxidase antibody followed by peroxidase detection with
diaminobenzidine (DAB). Tissues were counterstained with
Mayer’s hematoxylin.
Enzyme-linked immunosorbent assay (ELISA)
On day 42, blood was collected from the heart of mice and
clarified by centrifugation. The serum was stored at 280uC until
ready for cytokine analysis. Murine IL-12 (p70) and IFN-c
concentrations were measured using a standardized sandwich
ELISA method (BD Biosciences Pharmingen).
Figure 7. Enhancement of survival rate by WKYMVm, 5-FU, and mDCs in a heterotopic cancer animal model. (A) Survival rate of mice
treated with combinations of WKYMVm, 5-FU, and mDCs. Balb/c mice were inoculated with CT-26 cells (5610
5 cells/head) and treated with WKYMVm,
5-FU, and mDCs according to the protocol in Fig. 1A. (B) Adoptive transfer of CD8 T lymphocytes or NK cells can enhance the survival rate of triple
combination-treated heterotopic cancer animal model mice. Balb/c mice were inoculated with CT-26 cells (1610
6 cells/head) and treated with
WKYMVm, 5-FU, and mDCs according to the protocol in Fig. 1A, and isolated CD8 T lymphocytes (1610
6 cells/head) or NK cells (1610
6 cells/head)
were transferred into the tail vein. Survival rate was monitored for 80 days.
**, P,0.01,
***, P,0.001 compared with the control.
doi:10.1371/journal.pone.0030522.g007
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To deplete CD4, CD8 T cells and NK cells, mice were treated
with the corresponding antibody on days 21, 0, and 5 (where day
0 is the day of primary tumor inoculation). The monoclonal rat
anti-mouse CD4 (clone GK1.5), rat anti-mouse CD8 (clone 53-
6.7) and rat anti-mouse asialoGM1 antibodies were used for
immunodepletion. In the leukocyte depletion studies, 100 mgo f
anti-CD4, anti-CD8, or anti-asialoGM1 antibody was injected i.p.
into Balb/c mice.
Lung metastasis
For the heterotopic lung metastasis experiment, CT-26 cells
(5610
5 cells in 100 ml of PBS) were injected s.c. into the right flank
of Balb/c mice (n=8) on day 23. 5-FU, WKYMVm, and mDCs
were administered for 3 weeks, as described above for the
experiment to measure tumor volume. On day 42, mice were
sacrificed and tumor nodules on the surface of the lungs were
observed. For the metastatic cancer animal experiment, CT-26
cells were washed twice with PBS, and injected into the tail vein of
Balb/c mice (2610
5 cells in 100 ml of PBS). After 14 days, mice
were sacrificed and the lung was weighed.
Adoptive transfer
To obtain CT26 tumor-reactive CD8 T cells, Balb/c mice were
immunized three times (at 1-week intervals) with 1610
7 CT26
tumor lysates (s.c. injection). On 21 day, immunized mice were
sacrificed, and CD8 T cells or NK cells were isolated using CD8 T
cell isolation kit or NK cell isolation kit (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) from their spleen. For adoptive
therapy, tumors were established by s.c. injecting 5610
6 CT26
tumor cells on the right flank of Balb/c mice. Palpable tumors
(,5 mm in diameter) usually formed at the injection site after 4 to
5 days. Before triple combined treatment, purified CD8 T (1610
6
cell/100 ml) cells or NK (1610
6 cell/100 ml) cells transferred (i.v.
injection) to CT26 tumor-loaded mice and then begin with triple
combined treatment.
Data analysis
Results are presented as the mean 6 SEM of repeated
experiments. Statistical significance of differences was determined
using ANOVA. Survival data were analyzed using the log-rank
test. P,0.05 was considered statistically significant.
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